DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524744-36-00

Enrollment

Registered

2026-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring total hip arthroplasty for coxofemoral osteoarthritis

Brief summary

To measure doxycycline penetration in cancellous bone using the cancellous bone concentration/plasmatic concentration ratio

Detailed description

To mesure the concentration of Doxycycline in cortical bone using the cortical bone concentration/plasmatic concentration ratio, To measure the concentration of Doxycycline in synovial fluid using the synovial fluid concentration/plasmatic concentration ratio

Interventions

DRUGDOXYCYCLINE BIOGARAN 100 mg

DRUGcomprimé pelliculé sécable

DRUGDOXYCYCLINE ARROW 100 mg

DRUGcomprimé pelliculé

DRUGDOXYCYCLINE TEVA 100 mg

DRUGcomprimé sécable

DRUGDOXYCYCLINE SANDOZ 100 mg

DRUGGRANUDOXY 100 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To measure doxycycline penetration in cancellous bone using the cancellous bone concentration/plasmatic concentration ratio	—

Secondary

Measure	Time frame
To mesure the concentration of Doxycycline in cortical bone using the cortical bone concentration/plasmatic concentration ratio, To measure the concentration of Doxycycline in synovial fluid using the synovial fluid concentration/plasmatic concentration ratio	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 21, 2026